Dianthus Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
An interim analysis of the CAPTIVATE phase 3 trial in CIDP led to an early go decision, with efficacy surpassing expectations and a strong safety profile. Study design changes will expedite completion, and the program is well positioned for future milestones and competitive advantage.
-
Strong phase II data in MG and rapid recruitment in CIDP position the program for key milestones in 2024, with interim CIDP results expected in Q2 and MMN phase II data in the second half. Patient-friendly trial design and differentiation from competitors support a favorable outlook.
-
Major clinical milestones are expected in 2026 for CIDP, MMN, and DNTH212, with strong efficacy and safety positioning versus competitors. Commercial potential is significant, supported by a robust cash position extending into 2028.
-
Two clinical-stage autoimmune therapeutics are advancing, with claseprubart showing robust efficacy and superior potency in MG, CIDP, and MMN, and DNTH212 targeting diseases driven by both innate and adaptive immunity. Key data readouts and regulatory milestones are expected throughout the year.
Fiscal Year 2025
-
Recent phase II data has de-risked the pipeline, accelerating CIDP trial timelines and supporting a competitive efficacy profile. Key catalysts are expected in 2026, with ongoing optimization of dosing and trial design across neuromuscular programs.
-
Two autoimmune therapies are advancing, with Claseprubart showing strong phase II MG results and a phase III program set to test both biweekly and monthly dosing. DNTH212, targeting both innate and adaptive immunity, enters phase I soon. Key data readouts for MG, CIDP, and MMN are expected in 2026.
-
Claseprubart, a C1s inhibitor, is advancing to phase III for MG and CIDP, aiming for best-in-class efficacy, improved safety, and less frequent dosing. A new bifunctional fusion protein expands the pipeline, with multiple clinical readouts expected through 2027.
-
Claseprubart's phase 3 trials in gMG and CIDP are advancing, with new dosing strategies and streamlined trial designs driving faster enrollment and differentiation from competitors. Auto injector implementation and regulatory alignment are key priorities.
-
Significant phase II efficacy for claseprubart in MG supports advancement to phase III with optimized dosing and screening. Accelerated CIDP trial timelines and robust operational execution position the pipeline for potential paradigm shifts in neuromuscular disease treatment.
-
An exclusive license for DNTH212, a phase I-ready bifunctional BDCA2 and BAFF/APRIL inhibitor, was announced, expanding the pipeline with a best-in-class autoimmune therapeutic. Preclinical data show superior efficacy, and a phase I trial is set for Q4 2024, with results expected in H2 2026.
-
Phase II results for claseprubart in myasthenia gravis showed rapid, robust, and statistically significant efficacy at both 300 mg and 600 mg doses, with a strong safety profile and no serious infections. The 300 mg Q2-week dose will advance to phase III, with potential for monthly dosing based on early extension data.
-
DNTH103 is advancing in three neuromuscular indications, with key MG phase II data expected in September 2024. Market research highlights strong physician demand for robust efficacy, safety, and convenient self-administration. The product’s unique pathway selectivity and potency may offer competitive advantages.
-
DNTH103, a potent and selective C1s inhibitor, is advancing as a first-line biologic for neuromuscular diseases, with phase II MG data expected in September and additional readouts in MMN and CIDP in 2026. Strong in vitro potency, safety, and patient convenience differentiate it from competitors.
-
DNTH103, a selective classical pathway inhibitor, is advancing through late-stage trials in MG, CIDP, and MMN, with phase II MG results expected in September. The drug aims to combine best-in-class efficacy, safety, and convenience, targeting multi-billion dollar markets and supported by strong funding and external validation.
-
Leadership strengthened with a new CCO experienced in neurology launches. Lead program 103, a potent C1s inhibitor, is on track for key phase II data in myasthenia gravis by late 2024, with additional programs in CIDP and MMN advancing. Cash runway extends to H2 2027.
-
Dianthus is advancing DNTH103, a potent, long-acting C1s inhibitor, in three neuromuscular indications with major data readouts expected over the next year. The candidate is highly differentiated by safety, efficacy, and convenience, targeting a combined U.S. market of up to 200,000 patients.
-
DNTH103, a potent antibody targeting active C1s, is advancing through Phase 2 and 3 trials for MG, MMN, and CIDP, with key data readouts expected in late 2024 and 2026. The program differentiates itself with higher potency, less frequent dosing, and a streamlined trial design.
-
DNTH103, a selective C1s inhibitor, is advancing through phase II and III trials in MG, CIDP, and MMN, with key data readouts expected from late 2025 through 2026. The product aims to offer superior potency, safety, and dosing convenience, supported by strong financials and IP protection.
Fiscal Year 2024
-
Three clinical programs are progressing, with MG phase II data expected next year and CIDP advancing directly to phase III. The CIDP trial design addresses patient needs and regulatory strategy, while MG aims for best-in-class efficacy and safety. Cash runway extends to 2027.
-
DNTH103 is advancing through pivotal trials in CIDP, myasthenia gravis, and MMN, with a patient-friendly dosing profile and strong safety differentiation. Key data readouts are expected in 2025–2026, supported by a robust cash position and FDA alignment.
-
DNTH103, a potent C1s inhibitor, is advancing through phase II and III trials in MG, MMN, and CIDP, with a focus on superior dosing convenience, safety, and efficacy. Key data readouts are expected from 2025 to 2027, and further indication expansion is under evaluation.
-
The company is advancing DNTH103, a potent, selective classical pathway inhibitor, in phase 2 trials for MG, MMN, and CIDP, with data readouts expected through 2027. Recent competitor results have de-risked the approach, and a strong cash position supports ongoing development.
-
Next-generation complement therapeutics are advancing in three neuromuscular indications, with strong clinical execution, external validation, and robust funding. Key milestones include phase II MG data in 2025 and a CIDP strategy update this year.
-
DNTH103 is advancing through Phase II trials in myasthenia gravis, MMN, and CIDP, with new data showing superior potency and convenience over competitors. The program is well-funded through 2027, with key milestones and competitor data expected later this year.